These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38856753)

  • 1. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR and 3D-QSSR studies of thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as CDK4 inhibitors by CoMFA analysis.
    Cai BQ; Jin HX; Yan XJ; Zhu P; Hu GX
    Acta Pharmacol Sin; 2014 Jan; 35(1):151-60. PubMed ID: 24122012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
    He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
    Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
    Ai Y; Wang ST; Sun PH; Song FJ
    Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.
    Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T
    J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling studies of [4-(3
    Lv H; Du Y; Sheng X; Gao Z; Shen J
    Future Med Chem; 2021 Aug; 13(16):1317-1339. PubMed ID: 34210159
    [No Abstract]   [Full Text] [Related]  

  • 12. A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations.
    Susanti NMP; Damayanti S; Kartasasmita RE; Tjahjono DH
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
    Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
    J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives.
    Faris A; Hadni H; Ibrahim IM; Elhallaoui M
    J Biomol Struct Dyn; 2024 Jun; 42(9):4817-4833. PubMed ID: 37338041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
    Pasha FA; Neaz MM
    J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Shirvani P; Fassihi A
    J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.
    Zheng J; Kong H; Wilson JM; Guo J; Chang Y; Yang M; Xiao G; Sun P
    PLoS One; 2014; 9(4):e93704. PubMed ID: 24722522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
    Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
    Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
    Wang F; Ma Z; Li Y; Zhu S; Xiao Z; Zhang H; Wang Y
    J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.